Bioinformatics and systems-biology approach to identify common pathogenic mechanisms for COVID-19 and systemic lupus erythematosus

References

• Center for Systems Science and Engineering at Johns Hopkins University: COVID-19 dashboard; 2022. Available from: https://coronavirus.jhu.edu/map.html.
   Google Scholar
• Gustine JN, Jones D. Immunopathology of hyperinflammation in COVID-19. Am J Pathol. 2021; Jan191(1):1–14. PubMed PMID: 32919977; PubMed Central PMCID: PMCPMC7484812. eng. doi:10.1016/j.ajpath.2020.08.009
   PubMed Web of Science ®Google Scholar
• To KK, Sridhar S, Chiu KH, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microb Infect. 2021; Dec10(1):507–535. PubMed PMID: 33666147; PubMed Central PMCID: PMCPMC8006950. eng. doi:10.1080/22221751.2021.1898291
   PubMed Web of Science ®Google Scholar
• Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England). 2020; Feb 15395(10223):514–523. PubMed PMID: 31986261; PubMed Central PMCID: PMCPMC7159286. eng. doi:10.1016/S0140-6736(20)30154-9
   PubMed Web of Science ®Google Scholar
• Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Internal Med. 2020; Jun 2172(11):Itc81–itc96. PubMed PMID: 32479157; eng. doi:10.7326/AITC202006020
   PubMed Web of Science ®Google Scholar
• Arnaud L, Fagot JP, Mathian A, et al. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014; Nov13(11):1082–1089. PubMed PMID: 25172239; eng. doi:10.1016/j.autrev.2014.08.034
   PubMed Web of Science ®Google Scholar
• Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dental Clin N Am. 2013; Oct57(4):631–655. PubMed PMID: 24034070; eng. doi:10.1016/j.cden.2013.06.003
   PubMedGoogle Scholar
• Reyes Gil M, Barouqa M, Szymanski J, et al. Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020; Aug 33(8):e2017539. PubMed PMID: 32785632; eng. doi:10.1001/jamanetworkopen.2020.17539
   PubMed Web of Science ®Google Scholar
• Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021; Mar14(2):502–508. PubMed PMID: 32989903; PubMed Central PMCID: PMCPMC7536986. eng. doi:10.1111/cts.12908
   PubMed Web of Science ®Google Scholar
• Berzuini A, Bianco C, Paccapelo C, et al. Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood. 2020; Aug 6136(6):766–768. PubMed PMID: 32559762; PubMed Central PMCID: PMCPMC7414594. eng. doi:10.1182/blood.2020006695
   PubMed Web of Science ®Google Scholar
• Oliviero B, Varchetta S, Mele D, et al. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol. 2020; Oct17(10):1101–1103. PubMed PMID: 32879471; PubMed Central PMCID: PMCPMC7463104. eng. doi:10.1038/s41423-020-00542-2
   PubMed Web of Science ®Google Scholar
• Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020; Jun 4;5(11). PubMed PMID: 32329756; PubMed Central PMCID: PMCPMC7308057. eng. doi: 10.1172/jci.insight.138999.
   Web of Science ®Google Scholar
• Borges do Nascimento IJ, von Groote TC, O’Mathúna DP, et al. Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: a systematic review and series of meta-analyses. PLoS One. 2020;15(9):e0239235. PubMed PMID: 32941548; PubMed Central PMCID: PMCPMC7498028 eng. doi:10.1371/journal.pone.0239235
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Perricone C, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS One. 2012;7(9):e45934. PubMed PMID: 23029327; PubMed Central PMCID: PMCPMC3448702. eng. doi:10.1371/journal.pone.0045934
   PubMed Web of Science ®Google Scholar
• Bonometti R, Sacchi MC, Stobbione P, et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020; Sep24(18):9695–9697. PubMed PMID: 33015814; eng.
   PubMed Web of Science ®Google Scholar
• Marques CDL, Kakehasi AM, Pinheiro MM, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV brasil registry. RMD Open. 2021; Jan7(1):e001461. PubMed PMID: 33510041; PubMed Central PMCID: PMCPMC7844930. eng. doi:10.1136/rmdopen-2020-001461
   PubMed Web of Science ®Google Scholar
• Rúa-Figueroa I, Rúa-Figueroa D, Pérez-Veiga N, et al. Antimalarials exert a cardioprotective effect in lupus patients: insights from the spanish society of rheumatology lupus register (RELESSER) analysis of factors associated with heart failure. Semin Arthritis Rheum. 2022; Feb52:151946. PubMed PMID: 35033377; PubMed Central PMCID: PMCPMC8720299. eng. doi:10.1016/j.semarthrit.2021.11.012
   PubMed Web of Science ®Google Scholar
• Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020; Jul79(7):859–866. PubMed PMID: 32471903; PubMed Central PMCID: PMCPMC7299648. eng. doi:10.1136/annrheumdis-2020-217871
   PubMed Web of Science ®Google Scholar
• Carvalho JS, Dos Reis Neto ET, Kakehasi AM, et al. Factors associated with poor outcomes in SLE patients with COVID-19: data from ReumaCoV-Brazil register. Lupus. 2023; Jan32(1):42–53. PubMed PMID: 36300790; PubMed Central PMCID: PMCPMC9614598. eng. doi:10.1177/09612033221135884
   PubMed Web of Science ®Google Scholar
• Thompson RS, Wilkins L, Cheng E, et al. GSE215865 2022 [updated Dec 06, 2022]. Available from:https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi.
   Google Scholar
• Banerjee U, Rao P, Reddy M, et al. A 9-gene biomarker panel identifies bacterial coinfections in culture-negative COVID-19 cases. Mol Omics. 2022; Sep 2618(8):814–820. PubMed PMID: 35971789; eng. doi:10.1039/D2MO00100D
   PubMed Web of Science ®Google Scholar
• Majumder N, Deepak V, Hadique S, et al. Redox imbalance in COVID-19 pathophysiology. Redox Biol. 2022; Oct56:102465. PubMed PMID: 36116160; PubMed Central PMCID: PMCPMC9464257. eng. doi:10.1016/j.redox.2022.102465
   PubMed Web of Science ®Google Scholar
• Figgett WA, Monaghan K, Ng M, et al. Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. Clin Transl Immunology. 2019;8(12):e01093. PubMed PMID: 31921420; PubMed Central PMCID: PMCPMC6946916. eng. doi:10.1002/cti2.1093
   PubMed Web of Science ®Google Scholar
• Yang M, Wang P, Liu T, et al. High throughput sequencing revealed enhanced cell cycle signaling in SLE patients. Sci Rep. 2023; Jan 413(1):159. PubMed PMID: 36599883; PubMed Central PMCID: PMCPMC9812989. eng. doi:10.1038/s41598-022-27310-8
   PubMed Web of Science ®Google Scholar
• Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013; Jan41(Database issue):D808–15. (Database issue): PubMed PMID: 23203871; PubMed Central PMCID: PMCPMC3531103. eng.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017; Jan 445(D1):D362–d368. PubMed PMID: 27924014; PubMed Central PMCID: PMCPMC5210637. eng. doi:10.1093/nar/gkw937
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and Sub-networks from complex interactome. BMC Syst Biol. 2014;8 Suppl 4(Suppl 4):S11. PubMed PMID: 25521941; PubMed Central PMCID: PMCPMC4290687. eng.
   PubMedGoogle Scholar
• Simon I, Barnett J, Hannett N, et al. Serial regulation of transcriptional regulators in the yeast cell cycle. Cell. 2001; Sep 21106(6):697–708. PubMed PMID: 11572776; eng. doi:10.1016/S0092-8674(01)00494-9
   PubMed Web of Science ®Google Scholar
• Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004; May 14117(4):421–426. PubMed PMID: 15137936; eng. doi:10.1016/S0092-8674(04)00452-0
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; Jan 23116(2):281–297. PubMed PMID: 14744438; eng. doi:10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Tsang HF, Chan LWC, Cho WCS, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021; Jul19(7):877–888. PubMed PMID: 33306423; eng. doi:10.1080/14787210.2021.1863146
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res. 2021; Jun232:13–36. PubMed PMID: 33352298; PubMed Central PMCID: PMCPMC7749645. eng. doi:10.1016/j.trsl.2020.12.007
   PubMed Web of Science ®Google Scholar
• Bournia VK, Fragoulis GE, Mitrou P, et al. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. RMD Open. 2021; Nov7(3):e001694. PubMed PMID: 34728554; PubMed Central PMCID: PMCPMC8565571. eng. doi:10.1136/rmdopen-2021-001694
   PubMed Web of Science ®Google Scholar
• Lai CC, Sun YS, Chen WS, et al. Risk factors for mortality in systemic lupus erythematosus patients: analysis of adult and pediatric cohorts in Taiwan. J Chin Med Assoc. 2022; Nov 185(11):1044–1050. PubMed PMID: 36343272; eng. doi:10.1097/JCMA.0000000000000783
   PubMed Web of Science ®Google Scholar
• Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013; Oct22(12):1286–1294. PubMed PMID: 24098001; eng. doi:10.1177/0961203313493032
   PubMed Web of Science ®Google Scholar
• Caza T, Oaks Z, Perl A. Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol. 2014; Jul-Aug33(4):330–363. PubMed PMID: 24471448; eng. doi:10.3109/08830185.2013.863305
   PubMed Web of Science ®Google Scholar
• Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021; Mar80(3):384–391. PubMed PMID: 33051220; PubMed Central PMCID: PMCPMC7554412. eng. doi:10.1136/annrheumdis-2020-218946
   PubMed Web of Science ®Google Scholar
• Zen M, Fuzzi E, Astorri D, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020; Aug112:102502. PubMed PMID: 32527675; PubMed Central PMCID: PMCPMC7832807. eng. doi:10.1016/j.jaut.2020.102502
   PubMed Web of Science ®Google Scholar
• Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020; Jun79(6):837–839. PubMed PMID: 32332072; eng. doi:10.1136/annrheumdis-2020-217566
   PubMed Web of Science ®Google Scholar
• Thanou A, Sawalha AH. SARS-CoV-2 and systemic lupus erythematosus. Curr Rheumatol Rep. 2021; Jan 2823(2):8. PubMed PMID: 33511495; PubMed Central PMCID: PMCPMC7842169. eng. doi:10.1007/s11926-020-00973-w
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhu W, Chen W, et al. Prognostic value of BIRC5 in lung adenocarcinoma lacking EGFR, KRAS, and ALK mutations by integrated bioinformatics analysis. Dis Markers. 2019;2019:5451290–5451212. PubMed PMID: 31093306; PubMed Central PMCID: PMCPMC6481100. eng.
   PubMed Web of Science ®Google Scholar
• Kee JY, Hong SH. Ginsenoside Rg3 suppresses mast cell-mediated allergic inflammation via mitogen-activated protein kinase signaling pathway. J Ginseng Res. 2019; Apr43(2):282–290. PubMed PMID: 30976166; PubMed Central PMCID: PMCPMC6437450. eng. doi:10.1016/j.jgr.2018.02.008
   PubMed Web of Science ®Google Scholar
• Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci U S A. 2000; May 997(10):5167–5172. PubMed PMID: 10779557; PubMed Central PMCID: PMCPMC25800. eng. doi:10.1073/pnas.090102397
   PubMed Web of Science ®Google Scholar
• Ishikawa C, Senba M, Mori N. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma. Int J Oncol. 2018; Aug53(2):801–814. PubMed PMID: 29901068; eng.
   PubMed Web of Science ®Google Scholar
• Xiong M, Zhuang K, Luo Y, et al. KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway. Aging (Albany NY). 2019; Dec 1611(24):11905–11921. PubMed PMID: 31841120; PubMed Central PMCID: PMCPMC6949076. eng. doi:10.18632/aging.102505
   PubMedGoogle Scholar
• Samy A, Maher MA, Abdelsalam NA, et al. SARS-CoV-2 potential drugs, drug targets, and biomarkers: a viral-host interaction network-based analysis. Sci Rep. 2022; Jul 1312(1):11934. PubMed PMID: 35831333; PubMed Central PMCID: PMCPMC9279364. eng. doi:10.1038/s41598-022-15898-w
   PubMedGoogle Scholar
• Zhuang Z, Chen Q, Zhong X, et al. Ginsenoside Rg3, a promising agent for NSCLC patients in the pandemic: a large-scale data mining and systemic biological analysis. J Ginseng Res. 2023; Mar47(2):291–301. PubMed PMID: 36249948; PubMed Central PMCID: PMCPMC9553969. eng. doi:10.1016/j.jgr.2022.09.006
   PubMed Web of Science ®Google Scholar
• Ward SE, Curley GF, Lavin M, et al. Von willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021; Feb192(4):714–719. PubMed PMID: 33326604; eng. doi:10.1111/bjh.17273
   PubMed Web of Science ®Google Scholar
• Devreese KMJ, Linskens EA, Benoit D, et al. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020; Sep18(9):2191–2201. PubMed PMID: 32619328; PubMed Central PMCID: PMCPMC7361253. eng. doi:10.1111/jth.14994
   PubMed Web of Science ®Google Scholar
• Java A, Apicelli AJ, Liszewski MK, et al. The complement system in COVID-19: friend and foe? JCI Insight. 2020; Aug 6;5(15). PubMed PMID: 32554923; PubMed Central PMCID: PMCPMC7455060 Alexion Pharmaceuticals and Novartis Pharmaceuticals and serving as a consultant for Gemini Therapeutics. JPA reports serving as a consultant for Celldex Therapeutics, Clinical Pharmacy Services, Kypha Inc., Achillion Pharmaceuticals Inc., and BioMarin Pharmaceutical Inc. and stock or equity options in Compliment Corporation, Kypha Inc., Gemini Therapeutics, and AdMiRx Inc. AHJK reports personal fees (<$10,000) from Exagen Diagnostics Inc. and GlaxoSmithKline. eng. doi:10.1172/jci.insight.140711
   PubMed Web of Science ®Google Scholar
• Postal M, Vivaldo JF, Fernandez-Ruiz R, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020; Dec67:87–94. PubMed PMID: 33246136; PubMed Central PMCID: PMCPMC8054829. eng. doi:10.1016/j.coi.2020.10.014
   PubMed Web of Science ®Google Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020; Oct 23370(6515). PubMed PMID: 32972996; PubMed Central PMCID: PMCPMC7857397. eng. doi:10.1126/science.abd4585
   Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-Infected pneumonia in wuhan, China. Jama. 2020; Mar 17323(11):1061–1069. PubMed PMID: 32031570; PubMed Central PMCID: PMCPMC7042881. eng. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Saitoh T, Komano J, Saitoh Y, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe. 2012; Jul 1912(1):109–116. PubMed PMID: 22817992; eng. doi:10.1016/j.chom.2012.05.015
   PubMed Web of Science ®Google Scholar
• Jenne CN, Wong CH, Zemp FJ, et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe. 2013; Feb 1313(2):169–180. PubMed PMID: 23414757; eng. doi:10.1016/j.chom.2013.01.005
   PubMed Web of Science ®Google Scholar
• García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441. PubMed PMID: 32612615; PubMed Central PMCID: PMCPMC7308593. eng. doi:10.3389/fimmu.2020.01441
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; Mar 275(1):33. PubMed PMID: 32296069; PubMed Central PMCID: PMCPMC7100419. eng. doi:10.1038/s41392-020-0148-4
   PubMed Web of Science ®Google Scholar
• Zhang N, Li C, Hu Y, et al. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020; Jul-Aug22(6-7):231–235. PubMed PMID: 32387332; PubMed Central PMCID: PMCPMC7200352. eng. doi:10.1016/j.micinf.2020.05.001
   PubMed Web of Science ®Google Scholar
• Irvani SSN, Golmohammadi M, Pourhoseingholi MA, et al. Effectiveness of interferon beta 1a, compared to interferon beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Trials. 2020; Jun 321(1):473. PubMed PMID: 32493468; PubMed Central PMCID: PMCPMC7268172. eng. doi:10.1186/s13063-020-04382-3
   PubMed Web of Science ®Google Scholar
• Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect. 2020; Jun53(3):368–370. PubMed PMID: 32205092; PubMed Central PMCID: PMCPMC7156211. eng. doi:10.1016/j.jmii.2020.03.005
   PubMedGoogle Scholar
• Toor SM, Saleh R, Sasidharan Nair V, et al. T-cell responses and therapies against SARS-CoV-2 infection. Immunology. 2021; Jan162(1):30–43. PubMed PMID: 32935333; PubMed Central PMCID: PMCPMC7730020. eng. doi:10.1111/imm.13262
   PubMed Web of Science ®Google Scholar
• Nelson P, Rylance P, Roden D, et al. Viruses as potential pathogenic agents in systemic lupus erythematosus. Lupus. 2014; May23(6):596–605. PubMed PMID: 24763543; eng. doi:10.1177/0961203314531637
   PubMed Web of Science ®Google Scholar
• Esposito S, Bosis S, Semino M, et al. Infections and systemic lupus erythematosus. Eur J Clin Microbiol Infect Dis. 2014; Sep33(9):1467–1475. PubMed PMID: 24715155; eng. doi:10.1007/s10096-014-2098-7
   PubMed Web of Science ®Google Scholar
• Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012; Sep13(9):613–626. PubMed PMID: 22868264; eng. doi:10.1038/nrg3207
   PubMed Web of Science ®Google Scholar
• Francois M, Donovan P, Fontaine F. Modulating transcription factor activity: interfering with protein-protein interaction networks. Semin Cell Dev Biol. 2020; Mar99:12–19. PubMed PMID: 30172762; eng. doi:10.1016/j.semcdb.2018.07.019
   PubMed Web of Science ®Google Scholar
• Chen L, Heikkinen L, Wang C, et al. Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 2019; Sep 2720(5):1836–1852. PubMed PMID: 29982332; PubMed Central PMCID: PMCPMC7414524. eng. doi:10.1093/bib/bby054
   PubMed Web of Science ®Google Scholar
• Bisserier M, Milara J, Abdeldjebbar Y, et al. AAV1.SERCA2a gene therapy reverses pulmonary fibrosis by blocking the STAT3/FOXM1 pathway and promoting the SNON/SKI axis. Mol Ther. 2020; Feb 528(2):394–410. PubMed PMID: 31879190; PubMed Central PMCID: PMCPMC7001085. eng. doi:10.1016/j.ymthe.2019.11.027
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513–545. PubMed PMID: 24555472; PubMed Central PMCID: PMCPMC4313732. eng. doi:10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• Zhu JY, Wang G, Huang X, et al. SARS-CoV-2 Nsp6 damages drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis. Commun Biol. 2022; Sep 305(1):1039. PubMed PMID: 36180527; PubMed Central PMCID: PMCPMC9523645. eng. doi:10.1038/s42003-022-03986-6
   PubMed Web of Science ®Google Scholar
• Umar S, Palasiewicz K, Meyer A, et al. Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming. Cell Mol Life Sci. 2022; May 1979(6):301. PubMed PMID: 35588018; PubMed Central PMCID: PMCPMC9118817. eng. doi:10.1007/s00018-022-04329-8
   PubMed Web of Science ®Google Scholar
• Zheng Q, Wang D, Lin R, et al. IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA. Front Immunol. 2022;13:1013322. PubMed PMID: 36189314; PubMed Central PMCID: PMCPMC9520788. eng. doi:10.3389/fimmu.2022.1013322
   PubMedGoogle Scholar
• Liu Y, Li L, Song X. Exosomal circPVT1 derived from lung cancer promotes the progression of lung cancer by targeting miR-124-3p/EZH2 axis and regulating macrophage polarization. Cell Cycle. 2022; Mar21(5):514–530. PubMed PMID: 35025697; PubMed Central PMCID: PMCPMC8942510. eng. doi:10.1080/15384101.2021.2024997
   PubMed Web of Science ®Google Scholar
• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi:10.1056/NEJMra1100359
   PubMed Web of Science ®Google Scholar
• Gopal J, Muthu M, Sivanesan I. A comprehensive survey on the expediated anti-COVID-19 options enabled by metal Complexes-Tasks and trials. Molecules. 2023; Apr 1028(8):3354. PubMed PMID: 37110587; PubMed Central PMCID: PMCPMC10143858. eng. doi:10.3390/molecules28083354
   PubMed Web of Science ®Google Scholar
• Al-Motawa MS, Abbas H, Wijten P, et al. Vulnerabilities of the SARS-CoV-2 virus to Proteotoxicity-Opportunity for repurposed chemotherapy of COVID-19 infection. Front Pharmacol. 2020;11:585408. PubMed PMID: 33162891; PubMed Central PMCID: PMCPMC7581855. eng. doi:10.3389/fphar.2020.585408
   PubMed Web of Science ®Google Scholar
• Fitch CA, Platzer G, Okon M, et al. Arginine: its pKa value revisited. Protein Sci. 2015; May24(5):752–761. PubMed PMID: 25808204; PubMed Central PMCID: PMCPMC4420524. eng. doi:10.1002/pro.2647
   PubMed Web of Science ®Google Scholar
• Ahmad SI. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the coronavirus, COVID-19 infection. Med Hypotheses. 2020; Sep142:109754. PubMed PMID: 32438240; PubMed Central PMCID: PMCPMC7194918 competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. eng. doi:10.1016/j.mehy.2020.109754
   PubMed Web of Science ®Google Scholar
• Schälter F, Dürholz K, Bucci L, et al. Does methotrexate influence COVID-19 infection? Case series and mechanistic data. Arthritis Res Ther. 2021; Jun 1023(1):166. PubMed PMID: 34112217; PubMed Central PMCID: PMCPMC8190723. eng. doi:10.1186/s13075-021-02464-4
   PubMed Web of Science ®Google Scholar
• Selvaraj V, Dapaah-Afriyie K, Finn A, et al. Short-Term dexamethasone in sars-CoV-2 patients. R I Med J (2013). 2020; Jun 19103(6):39–43. PubMed PMID: 32570995; eng.
   PubMedGoogle Scholar
• Ferreto LED, Bortoloti DS, Fortes PCN, et al. Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis. Sao Paulo Med J. 2021;139(6):657–661. PubMed PMID: 34644768; PubMed Central PMCID: PMCPMC9634846. eng. doi:10.1590/1516-3180.2021.0120.r1.30062021
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021; Apr70(4):725–732. PubMed PMID: 33082265; PubMed Central PMCID: PMCPMC8136807. eng. doi:10.1136/gutjnl-2020-322539
   PubMed Web of Science ®Google Scholar
• Devaux CA, Melenotte C, Piercecchi-Marti MD, et al. Cyclosporin A: a repurposable drug in the treatment of COVID-19? Front Med (Lausanne). 2021;8:663708. PubMed PMID: 34552938; PubMed Central PMCID: PMCPMC8450353. eng. doi:10.3389/fmed.2021.663708
   PubMed Web of Science ®Google Scholar
• Szente Fonseca SN, de Queiroz Sousa A, Wolkoff AG, et al. Risk of hospitalization for covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. Travel Med Infect Dis. 2020; Nov-Dec38:101906. PubMed PMID: 33137493; PubMed Central PMCID: PMCPMC7604153. eng. doi:10.1016/j.tmaid.2020.101906
   PubMed Web of Science ®Google Scholar
• Vaira LA, Hopkins C, Petrocelli M, et al. Efficacy of corticosteroid therapy in the treatment of long- lasting olfactory disorders in COVID-19 patients. Rhinology. 2021; Feb 159(1):21–25. PubMed PMID: 33290446; eng.
   PubMed Web of Science ®Google Scholar
• Ugarte-Gil MF, Alarcón GS, Izadi Z, et al. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis. 2022; Jul81(7):970–978. PubMed PMID: 35172961; PubMed Central PMCID: PMCPMC8882632. eng. doi:10.1136/annrheumdis-2021-221636
   PubMed Web of Science ®Google Scholar
• Saggi SJ, Nath S, Culas R, et al. Early experience with methylprednisolone on SARS-CoV-2 infection in the african American population, a retrospective analysis. Clin Med Insights Circ Respir Pulm Med. 2020;14:1179548420980699. PubMed PMID: 33402859; PubMed Central PMCID: PMCPMC7745550. eng.
   Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020; Nov 19383(21):2030–2040. PubMed PMID: 33031652; PubMed Central PMCID: PMCPMC7556338. eng.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; May 14369:m1849. PubMed PMID: 32409561; PubMed Central PMCID: PMCPMC7221473 at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work other than those listed above; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. eng.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-Moderate covid-19. N Engl J Med. 2020; Nov 19383(21):2041–2052. PubMed PMID: 32706953; PubMed Central PMCID: PMCPMC7397242. eng. doi:10.1056/NEJMoa2019014
   PubMed Web of Science ®Google Scholar
• Bellos I. A metaresearch study revealed susceptibility of covid-19 treatment research to white hat bias: first, do no harm. J Clin Epidemiol. 2021; Aug136:55–63. PubMed PMID: 33775812; PubMed Central PMCID: PMCPMC7997163. eng. doi:10.1016/j.jclinepi.2021.03.020
   PubMed Web of Science ®Google Scholar
• Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003; Nov3(11):722–727. PubMed PMID: 14592603; PubMed Central PMCID: PMCPMC7128816. eng. doi:10.1016/S1473-3099(03)00806-5
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015; Oct23(5):231–269. PubMed PMID: 26246395; eng. doi:10.1007/s10787-015-0239-y
   PubMed Web of Science ®Google Scholar
• Carbajo-Lozoya J, Müller MA, Kallies S, et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012; Apr323(1):198952–198117. PubMed PMID: 22349148; PubMed Central PMCID: PMCPMC7114512. eng.
   Google Scholar
• Ohgushi M, Ogo N, Yanagihara T, et al. Tacrolimus treatment for Post-COVID-19 interstitial lung disease. Intern Med. 2022; Feb 1561(4):585–589. PubMed PMID: 34866097; PubMed Central PMCID: PMCPMC8907778. eng. doi:10.2169/internalmedicine.7971-21
   PubMed Web of Science ®Google Scholar
• Chalklin CG, Koimtzis G, Khalid U, et al. SARS-CoV-2 infection can lead to an increase in tacrolimus levels in renal transplant patients: a cohort study. Transpl Int. 2022;35:10127. PubMed PMID: 35387396; PubMed Central PMCID: PMCPMC8977848. eng. doi:10.3389/ti.2022.10127
   PubMed Web of Science ®Google Scholar